Cargando...
盐酸埃克替尼治疗EGFR突变状态明确的晚期非小细胞肺癌的临床观察
BACKGROUND AND OBJECTIVE: Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer. Compared to the other two commercially available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them...
Gardado en:
| Publicado en: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
中国肺癌杂志编辑部
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6015183/ https://ncbi.nlm.nih.gov/pubmed/26706949 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.04 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|